PIK3CA and neoplasm: Concerning MBC, the US Food and Drug Administration approved both alpelisib and a companion diagnostic test (therascreen PIK3CA RGQ PCR Kit, Qiagen, Chatsworth, CA, USA) to detect PIK3CA mutations in tumor and/or plasma samples.